In a mouse modelof ICH, bosutinib inhibits salt-inducible kinase-2 (SIK-2), attenuatesinflammation, and is associated with better pathological outcomes.21 Bosutinib has been related to treatment-associated vascular adverseeffects such as cerebral ischemia, myocardial infarction, and pulmonaryhypertension although with a milder frequency than other tyrosine kinaseinhibitors. Here, SIK2 is linked to myocardial infarction.